Corporate Banner
Satellite Banner
Informatics
Scientific Community
 
Become a Member | Sign in
Home>News>This Article
  News
Return

TEMIS Acquires i3 Analytics

Published: Monday, July 01, 2013
Last Updated: Monday, July 01, 2013
Bookmark and Share
TEMIS complements leading-edge Luxid® semantic content enrichment platform with best-in-class data analytics and visualization capabilities.

TEMIS has announced that they have acquired the US-based i3 Analytics, a provider of advanced data analytics and visualization technologies, for an undisclosed amount.

Founded in 2011 and employing former NIH (National Institutes of Health) engineers, i3 Analytics provides the award-winning Biopharma Navigator, a Software-as-a-Service platform that charts the biopharma landscape based on Life Sciences open data.

Providing customers with tailor-made, relevant and intuitive visualization maps, the i3 Analytics' Biopharma Navigator enables Life Sciences professionals to work faster, provide critical information to their peers, and make fast and informed clinical, regulatory, and business decisions.

Awarded "Best Semantic Technology Solution" in January 2013 by the Software and Information Industry Association (SIIA) for its flagship platform Luxid®, TEMIS has developed an in-depth expertise serving the information extraction and semantic enrichment needs of a varied range of industries, including Defence, Publishing & Media, as well as Life Sciences, where demand for easy-to-use, intuitive visualization and analytics tools has been growing in step with the exponential growth of available unstructured content.

This acquisition reinforces TEMIS' commitment and capabilities to serving its customers by strengthening its product range with a complementary SaaS Analytics and Discovery offering and expanding its know-how with the integration of a team of former NIH engineers.

The acquisition will also enable TEMIS to accelerate its penetration into new application areas in Life Sciences.

"The acquisition of i3 Analytics demonstrates our commitment to the Life Sciences market", said Eric Brégand, CEO of TEMIS.

Brégand continued, "This transaction creates a best-in-class offering for our Life Sciences customers, based on the winning combination of deep computational linguistics expertise and leading-edge data visualization know-how. And we will be transposing the solution to other verticals where data analytics and information visualization are also becoming critical."

Moving forward, and with a focus on maintaining its commitment to simplicity and innovation, TEMIS will integrate the SaaS Biopharma Navigator into its Luxid® product line and make it available for other application segments.


Further Information
Access to this exclusive content is for Technology Networks Premium members only.

Join Technology Networks Premium for free access to:

  • Exclusive articles
  • Presentations from international conferences
  • Over 2,400+ scientific posters on ePosters
  • More than 3,700+ scientific videos on LabTube
  • 35 community eNewsletters


Sign In



Forgotten your details? Click Here
If you are not a member you can join here

*Please note: By logging into TechnologyNetworks.com you agree to accept the use of cookies. To find out more about the cookies we use and how to delete them, see our privacy policy.

Related Content

Bloomberg BNA Selects TEMIS for Content Categorization and Enrichment
Leading legal publisher applying powerful Luxid® Content Enrichment solution to vast archive.
Wednesday, April 17, 2013
TEMIS Named SIIA CODiE Award Finalist for Best Semantic Technology Solution
Luxid® content enrichment platform earns prestigious content industry recognition.
Friday, January 11, 2013
TEMIS Selected to Provide Semantic Indexing and Content Enrichment Solution for Gannett
Gannett to deploy Luxid® across the company’s digital properties enterprise-wide, including USATODAY.COM.
Thursday, April 05, 2012
HCPro Partnering with TEMIS to Boost Power of New Compliance Products
HCPro adds TEMIS semantic content enrichment capabilities.
Monday, December 19, 2011
Scientific News
New Tool Uses 'Drug Spillover' to Match Cancer Patients with Treatments
Researchers have developed a new tool that improves the ability to match drugs to disease: the Kinase Addiction Ranker (KAR) predicts what genetics are truly driving the cancer in any population of cells and chooses the best "kinase inhibitor" to silence these dangerous genetic causes of disease.
Computer Model Could Explain how Simple Molecules Took First Step Toward Life
Two Brookhaven researchers developed theoretical model to explain the origins of self-replicating molecules.
The Mystery of the Instant Noodle Chromosomes
Researchers from the Lomonosov Moscow State University evaluated the benefits of placing the DNA on the principle of spaghetti.
Web App Helps Researchers Explore Cancer Genetics
Brown University computer scientists have developed a new interactive tool to help researchers and clinicians explore the genetic underpinnings of cancer.
An Innovative Algorithm to Decipher How Drugs Work Inside the Body
Researchers at Columbia University Medical Center (CUMC) have developed a computer algorithm that is helping scientists see how drugs produce pharmacological effects inside the body.
How do Networks Shape the Spread of Disease and Gossip?
A team of mathematicians from Oxford University, University of North Carolina at Chapel Hill, and Rutgers University used a set of mathematical rules to encode how a contagion spreads, and then studied the outcomes of these rules.
AncestryDNA and Calico to Research the Genetics of Human Lifespan
Collaboration will analyze family history and genetics to facilitate development of cutting-edge therapeutics.
Informatics Tool Helps Scientists Prioritize Protein Modification Research
Researchers have developed a new informatics technology that analyzes existing data repositories of protein modifications and 3D protein structures to help scientists identify and target research on "hotspots" most likely to be important for biological function.
Software Differences can Skew Medical Scan Results
Differences in software can significantly skew results of medical scans commonly used in clinical care and research.
AMRI, PerkinElmer to Collaborate on Drug Discovery
Albany Molecular Research (AMRI) and PerkinElmer are collaborating to provide drug discovery infrastructure and services in AMRI's newly launched drug discovery center.
Scroll Up
Scroll Down
SELECTBIO

Skyscraper Banner
Go to LabTube
Go to eposters
 
Access to the latest scientific news
Exclusive articles
Upload and share your posters on ePosters
Latest presentations and webinars
View a library of 1,800+ scientific and medical posters
2,400+ scientific and medical posters
A library of 2,500+ scientific videos on LabTube
3,700+ scientific videos
Close
Premium CrownJOIN TECHNOLOGY NETWORKS PREMIUM FREE!